- Home
- ZEPP vs RAPT Comparison
ZEPP vs RAPT Comparison
Compare ZEPP & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEPP
- RAPT
- Stock Information
- Founded
- ZEPP 2013
- RAPT 2015
- Country
- ZEPP Netherlands
- RAPT United States
- Employees
- ZEPP N/A
- RAPT N/A
- Industry
- ZEPP Computer Manufacturing
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- ZEPP Technology
- RAPT Health Care
- Exchange
- ZEPP Nasdaq
- RAPT Nasdaq
- Market Cap
- ZEPP 148.3M
- RAPT 122.9M
- IPO Year
- ZEPP N/A
- RAPT 2019
- Fundamental
- Price
- ZEPP $11.13
- RAPT $13.31
- Analyst Decision
- ZEPP
- RAPT Buy
- Analyst Count
- ZEPP 0
- RAPT 5
- Target Price
- ZEPP N/A
- RAPT $36.75
- AVG Volume (30 Days)
- ZEPP 1.4M
- RAPT 133.4K
- Earning Date
- ZEPP 08-03-2025
- RAPT 08-07-2025
- Dividend Yield
- ZEPP N/A
- RAPT N/A
- EPS Growth
- ZEPP N/A
- RAPT N/A
- EPS
- ZEPP N/A
- RAPT N/A
- Revenue
- ZEPP $181,183,000.00
- RAPT N/A
- Revenue This Year
- ZEPP $758.69
- RAPT N/A
- Revenue Next Year
- ZEPP N/A
- RAPT N/A
- P/E Ratio
- ZEPP N/A
- RAPT N/A
- Revenue Growth
- ZEPP N/A
- RAPT N/A
- 52 Week Low
- ZEPP $2.06
- RAPT $5.67
- 52 Week High
- ZEPP $15.85
- RAPT $27.84
- Technical
- Relative Strength Index (RSI)
- ZEPP 64.77
- RAPT 69.39
- Support Level
- ZEPP $10.42
- RAPT $10.00
- Resistance Level
- ZEPP $15.85
- RAPT $14.09
- Average True Range (ATR)
- ZEPP 2.13
- RAPT 1.04
- MACD
- ZEPP 0.10
- RAPT 0.42
- Stochastic Oscillator
- ZEPP 60.20
- RAPT 87.32
About ZEPP Zepp Health Corporation
Zepp Health Corp is engaged in the business of manufacturing smart health wearable products. The company operates in one segment which is Amazfit-branded products. The product portfolio includes smartwatches and fitness bands.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.